Please login to the form below

Not currently logged in
Email:
Password:

Novartis completes sale of animal health unit to Lilly

$5.4bn deal is finalised
elanco headquarters animal health lilly

Elanco is Lilly's animal health unit

US pharma company Lilly has completed the acquisition of the animal health business from Swiss rival Novartis.

Novartis announced the sale of the unit in April last year as part of a wider range of deals that included the purchase of GlaxoSmithKline's oncology business in part exchange for its vaccines division and the creation of a joint venture formed from GSK and Novartis' consumer health divisions.

The completion of the deal, worth $5.4bn, strengthens Lilly's own animal health business which operates under the name Elanco.

The company now takes ownership of a unit that achieved mid-single digit growth in the third quarter of 2014, contributing to total consumer health sales of $1.1bn for the period.

In addition to acquiring Novartis' portfolio of animal health products, which include medicines for both pets and livestock, Lilly's Elanco will also take control of new facilities, bringing its capabilities to 17 manufacturing sites and 14 R&D locations.

"As a top-tier animal health company, we are better positioned to help our customers respond to the changing external environment and meet increasing demands for animal protein, as well as growing desires for pet ownership," said Jeff Simmons, president of Elanco Animal Health.

Simmons also highlighted the greater diversification of Elanco, which now looks to have an even split in revenues between products for pets and products for livestock.

As previously announced former head of animal health at Novartis George Gunn will retire now the deal is complete.

Several major pharma companies have reshaped their animal health businesses in the past couple of years.

In 2012 Bayer purchased Teva's animal health division while Sanofi acquired India-based Dosch Pharmaceuticals to boost their respective businesses.

By contrast Pfizer has chosen to distance itself from animal health choosing to spin out its business Zoetis as an independent firm.

Article by
Thomas Meek

8th January 2015

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Pegasus

Pegasus inspires healthy decisions through creative, inspirational and integrated communications. Working with ambitious clients, we deliver big ideas and far-reaching...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics